Active Ageing and Self-Management of Health (including integrated care)

Jerome de Barros
NCP Health

Innovate UK
H2020 Research priorities 2016/2017

- Promoting Healthy Ageing
- Personalised medicine
- Health ICT
- Human Biomonitoring
SC1 Work Programme 2016/2017 in brief (1/2)

- **Call “Personalised Medicine”**
  - **21 Call topics** (34 in 2014/2015): 10 in 2016, 10 in 2017, 1 open in 2016 & 2017
  - **2 SME Instrument topics:**
    - Supporting innovative SMEs in the healthcare biotechnology sector (Cell technologies in medical applications and biomarkers)
    - **Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well**

**Budget**
- €500.17M (2016)
- €433.81M (2017)
### SC1 Work Programme 2016/2017 in brief (1/2)

<table>
<thead>
<tr>
<th>Call</th>
<th>Budget</th>
<th>Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PM-12–2016</strong>: PCP - eHealth innovation in empowering the hospitalised patient</td>
<td>€18M</td>
<td>16 Feb. 2016</td>
</tr>
<tr>
<td><strong>PM-13–2016</strong>: PPI for deployment and scaling up of ICT solutions for active and healthy ageing</td>
<td>€10.5M</td>
<td>16 Feb. 2016</td>
</tr>
<tr>
<td><strong>PM-14–2016</strong>: EU-Japan cooperation on Novel ICT Robotics based solutions for active and healthy ageing at home or in care facilities</td>
<td>€5M</td>
<td>13 Apr. 2016</td>
</tr>
<tr>
<td><strong>PM-21-2016</strong>: Implementation research for scaling-up of evidence based innovations and good practice in Europe and low- and middle-income countries</td>
<td>€40M</td>
<td>13 Apr. 2016</td>
</tr>
</tbody>
</table>
Example Call topic

**Specific Challenge:** Chronic diseases represent a significant burden on individuals and healthcare systems in the European Union and beyond. Innovative and effective therapeutic approaches are required to provide the best quality of care when prevention strategies fail. While considerable basic knowledge has been generated by biomedical research in recent years, the development of new therapies is stagnating, in part due to a lack of clinical validation.

**Scope:** Proposals should focus on clinical trial(s), supporting proof of concept of clinical safety and efficacy in humans of novel therapies (pharmacological as well as non-pharmacological) or the optimisation of available therapies (e.g. repurposing) for chronic non-communicable or chronic infectious diseases. Preclinical research should be completed before the start of the project. Proposals should provide a sound feasibility assessment, justified by available publications or provided preliminary results. Gender and age must be considered whenever relevant. Due consideration should also be paid to involve patients and take their views into account wherever relevant. Rare diseases and regenerative medicine are not within the scope of this topic.

The Commission considers that proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

**Expected Impact:** New or optimised therapeutic strategies, adapted where relevant to the different needs of men, women, children and elderly, with the highest potential to generate advances in clinical practice and care for chronic non-communicable or chronic infectious diseases. Improve the therapeutic outcome of major chronic health issues with significant impact on disease burden of individual patients and health care systems.

**Type of Action:** Research and Innovation action
How to read the calls

- **Call title**
  - This is the problem to be addressed

- **Specific Challenge**
  - This explains the reason for the challenge

- **Scope**
  - This provides some insights to possible approaches / solutions
  - It is not very prescriptive
  - Look for acronyms, legislation, specific countries, other EC initiatives
  - It will indicate the expected size of the project e.g. Euro 3 million

- **Expected impact**
  - This is what the project **must deliver**
  - You must justify how your approach is the best way to achieve these impacts
Innovation Procurement in Horizon 2020

Public procurement is 'the tool' that enables potential buyers to steer industry R&I to its needs. However, it is under-used in EU.
Pre-Commercial Procurement (PCP) to steer the development of solutions towards concrete public sector needs, whilst comparing/validating alternative solution approaches from various vendors.

Public Procurement of Innovative Solutions (PPI) to act as launching customer/early adopter/first buyer of innovative commercial end-solutions newly arriving on the market.
Participation Requirements

- Minimum of 3 independent participants from 3 different MS or AC, of which minimum 2 public procurers (buyers group) from 2 different MS or AC
  - Public procurers are contracting authorities or contracting entities as define in the EU public procurement directives

- They can be complemented by other types of procurers that are providing services of public interest and share the same need to procure R&D or innovative
  - E.g. NGOs or private procurers

- Other entities may participate as direct beneficiaries if they add value to the action, are not potential suppliers of solutions sought for by the PCP and have no other type of conflict of interest
Specificities PCP

- Funded activities: Preparation and implementation of the joint PCP
  - Price of the R&D services procured via the joint PCP
  - Costs of the eligible coordination and networking activities (which may include in-kind contributions of third parties linked to grant beneficiaries)
  - Funding rate: 90% of the total eligible costs to leverage co-financing from the procurers
  - Requested reimbursement of eligible costs of coordination and networking activities should not exceed 30% of the requested grant
  - Indirect eligible costs are calculated as a flat rate of 25% of direct eligible costs
Specificities PPI

- Funded activities: Preparation and implementation of the joint PPI
  - Price of the innovative solutions procured via the joint PPI
  - Costs of the eligible coordination and networking activities (which may include in-kind contributions of third parties linked to grant beneficiaries)
  - Cost for procurement of R&D are not eligible
  - Funding rate: 35% of the total eligible costs to leverage co-financing from the procurers
  - Requested reimbursement of eligible costs of coordination and networking activities should not exceed 50% of the requested grant
  - Indirect eligible costs are calculated as a flat rate of 25% of direct eligible costs
Specificities PCP/PPI

- Different Proposal template
  - 90 Pages max for section 1,2,3
  - Different headings in Part B

- Important: Annex E - Specific requirements for innovation procurement (PCP/PPI) supported by Horizon 2020 grants
  - Tender documentation
  - Procurement procedure
  - Contract implementation, etc.
PM-12–2016: PCP - eHealth innovation in empowering the hospitalised patient

- **Specific Challenge**
  - Empowering the hospitalised patients, outpatients and their families/carers **to support a continuum of care** across a range of services
    - relieve the pressure on governments to provide more cost-effective healthcare systems by improving utilisation of healthcare and health outcomes.
    - support for patients should be understood broadly covering a continuum of care in hospital, in outpatient care, and integration back to working life.
  - eHealth action plan 2012-2020 and the outcome of the mHealth Green paper pave the way towards empowerment of the patient with the assistance of ICT
PM-12–2016: PCP - eHealth innovation in empowering the hospitalised patient

**Scope**

- Enable transition to new services or better integration of existing services through appropriate ICT based technologies using relevant elements e.g., proof of concept, user acceptance, use of the service, training of the professionals including online courses/forums etc.,
- Increase the level of interactions between the patient and the health professionals or informal carers
- Examples: telemedicine services to follow patients, e-mental health, domestic rehabilitation (but not only)
- Give the patient tools to take major life decisions and actively participate on the treatment and recovery from the disease
PM-12–2016: PCP - eHealth innovation in empowering the hospitalised patient

- **Impact**
  - Improve the quality and cost-effectiveness of healthcare systems
  - Reduced fragmentation of demand to facilitate PCPs (min EUR 3 million) by **leveraging resources** (i.e. synergies with Structural Funds)
  - Aim for **interoperable solutions** that are validated through field testing by participating procurers in **multiple countries across Europe** and contribution to **standardisation**
  - Ensure **equal access rights** to the results generated by the PCP for **all** procurers
PM-12–2016: PCP - eHealth innovation in empowering the hospitalised patient

- Submission deadline: 13 Apr. 2016
- Pre-Commercial Procurement
- Indicative budget: 18 M€
- Suggested funding request: around 4M€
PM-13–2016: PPI for deployment and scaling up of ICT solutions for active and healthy ageing

- Specific Challenge
  - Scale up of innovative solutions,
    • which have been tested
    • have demonstrated success in smaller scale settings
    • have not yet been deployed on a large scale,
  - These include: inter alia integrated care and active ageing solutions, independent living solutions and telecare, support for self-care and person-centred care.
  - Ensure take-up of these ICT-based solutions by both public care providers as well as people in need for care
PM-13–2016: PPI for deployment and scaling up of ICT solutions for active and healthy ageing

- **Scope**
  - contribute to the Scaling-Up Strategy of the EIP AHA and to boosting the Silver Economy and Digital Single Market in Europe
  - target deployment of active and healthy ageing solutions at large scale across different regions in Europe
  - Scope of pilots: to specify, purchase and deploy ICT based solutions for active and healthy ageing which can deliver sustainable, new or improved services in which public procurement approaches for innovative solutions are successfully applied.
PM-13–2016: PPI for deployment and scaling up of ICT solutions for active and healthy ageing

- **Impact**
  - Contribution with data and experiences to regulatory and legislative process development
  - Contribution to socio-economic evidence base for ICT investments in the field (cost-benefit analysis, QoL, etc.)
  - Support initiatives on interoperability and standardisation (see Action 77 of Digital Agenda for Europe)
  - Support sustainability of Healthcare and emergence of new business models to develop ICT innovation for AHA
  - Contribute to inform policy measures that foster the take-up of solutions
PM-13–2016: PPI for deployment and scaling up of ICT solutions for active and healthy ageing

- Submission deadline: 13 Apr. 2016
- Public Procurement of Innovative solutions
- Indicative budget: 10.5 M€
- Suggested funding request: 2-5M€
PM-14–2016: EU-Japan cooperation on Novel ICT Robotics based solutions for AHA at home or in care facilities

Specific Challenge
- Citizens in ageing European and Japanese populations wish to stay in their homes for as long as possible. They are however at risk of age related impairments such as poor health, cognitive impairment, frailty and social exclusion, etc.
PM-14–2016: EU-Japan cooperation on Novel ICT Robotics based solutions for AHA at home or in care facilities

- **Scope**
  - Joint research and innovation proposals for **developing and demonstrating advanced** ICT Robotics based solutions for extending active and healthy ageing in daily life.
  - Combine multi-disciplinary research **involving** behavioural, sociological, health and other relevant disciplines.
  - Characteristics of solutions developed described
PM-14–2016: EU-Japan cooperation on Novel ICT Robotics based solutions for AHA at home or in care facilities

- **Impact**
  - To extend independence and autonomy of older persons in need of care (through reduction of admissions and days spent in care institutions, and prolongation of time spent living in own home when ageing with emerging functional and/or mental impairments)
  - To provide high quality service corresponding to the needs in daily lives of older persons.
  - To improve quality of life of older persons and their carers.
  - To reduce caregivers burden
  - Improvement of efficiency in care provision
  - Global leadership
PM-14–2016: EU-Japan cooperation on Novel ICT Robotics based solutions for AHA at home or in care facilities

- Submission deadline: 13 Apr. 2016
- Research and Innovation Action
- Indicative budget: 5 M€
- Suggested funding request: 1-2M€ (European side)
PM-21-2016: Implementation research for scaling-up of evidence based innovations and good practice in Europe and low- and middle-income countries

- Specific Challenge
  - The uptake of well-researched and proven interventions addressing current challenges in the field of Health systems is still slow in Europe and low- and middle-income countries
  - Implementation Research - The scientific study of methods to promote the uptake of research findings – can be a valuable tool
PM-21-2016: Implementation research for scaling-up of evidence based innovations and good practice in Europe and low- and middle-income countries

- **Scope**
  - Replicate and scale up a comprehensive intervention in the field of health systems that is 1) innovative and 2) well-researched, 3) supported by sufficient documented evidence.
  - Micro-level interventions, e.g. to promote a specific therapeutic regimen for a single disease are NOT covered.
  - Identify the facilitators of and barriers to scaling-up, including context-specific factors and differing social and health systems environments.
  - Multidisciplinary, diversity of regions involved (EU and outside)
  - Strong end-user involvement during project expected.
PM-21-2016: Implementation research for scaling-up of evidence based innovations and good practice in Europe and low- and middle-income countries

- **Impact**
  - improving the functioning and sustainability of health systems, and greater health equity and additional societal benefits
  - Provide validated framework and strategy for a large-scale implementation of intervention
PM-21-2016: Implementation research for scaling-up of evidence based innovations and good practice in Europe and low- and middle-income countries

- Submission deadline: 13 Apr. 2016
- Research and Innovation Action
- Indicative budget: 40 M€
- Suggested funding request: 4-6M€ (European side)
Other funding initiatives

AAL Programme

Eurostars

JPND Research

EU Joint Programme – Neurodegenerative Disease Research

More Years Better Lives
We can’t stop thinking about the future

Jerome de Barros – Horizon 2020 Health NCP  
Mobile: 44(0)7799766352  
Email: jerome.debarros@innovateuk.gov.uk

Innovate UK

North Star House, North Star Avenue, Swindon SN2 1UE  
Tel: +44 (0)1793 442 700  
Email: support@innovateuk.gov.uk  
www.innovateuk.gov.uk